InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,951.20
(
0.53%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.45
(
0.04%
)
Bitcoin
56,556.41
(
-0.26%
)
Post# of 252525
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119992
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 09/21/2018 9:44:07 AM

Friday, September 21, 2018 9:44:07 AM

Post# of 252525
YMAB IPOs 6.90M* shares @$16.00:

https://www.ymabs.com/page/release/y-mabs-therapeutics-announces-pricing-of-initial-public-offering/

Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates, naxitamab and omburtamab, which target tumors that express GD2 and B7-H3, respectively.

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up